Prime Medicine says FDA clears IND for PM577a in Wilson disease trial

Reuters2026/07/23 20:13

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Prime Medicine won FDA clearance of its IND for PM577a, an in vivo prime editor targeting H1069Q-mutated Wilson disease.
The decision enables a global Phase 1/2 program with its previously cleared New Zealand CTA.
Trial start is slated for H2 2026; initial clinical data are expected in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prime Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607231605PRIMZONEFULLFEED9767379) on July 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Prime Medicine says FDA clears IND for PM577a in Wilson disease trial

You may also like

Crypto prices